HIF1A and breast carcinoma: Peptides that derive from HIF-1α C-TAD (aa 766–826 and aa 786–826) or p300 CH1 peptides reduced EPO promoter activity when overexpressed in HCT-116 colon and MDA-MB435 breast carcinoma cell lines [125].